Citations

Clear

1432 citation(s) found for "Uk, Nathan".

Simulation‐free workflow for lattice radiation therapy using deep learning predicted synthetic computed tomography: A feasibility study
Yu, Nathan Y. , Ashman, Jonathan B. , Toesca, Diego Santos, Deufel, Christopher L. , Duan, Jingwei , Chen, Quan , Rong, Yi , Chen, Quan , Ahmed, Safia K. , Duan, Jingwei , Rong, Yi , Toesca, Diego A.S. , Zhu, Libing , Grams, Michael P.

Mayo Clinic

Journal of Applied Clinical Medical Physics | June 12, 2025 | Volume: 26 | Issue: 7 | Pages: No page available

10.1002/acm2.70137 | PMID 40504103 Get It

Abstract Purpose Lattice radiation therapy (LRT) is a form of spatially fractionated radiation therapy that allows increased total dose delivery aiming for improved treatment response without an increase in toxicities, commonly utilized for palliation of bulky tumors. The LRT treatment planning process is complex, while eligible patients often have an urgent need for expedited treatment start. In this study, we aimed to develop a simulation‐free workflow for volumetric modulated arc therapy (VMAT)‐based LRT planning via deep learning‐predicted synthetic CT (sCT) to expedite treatment initiation. Methods Two deep learning models were initially trained using 3D U‐Net architecture to generate sCT from diagnostic CTs (dCT) of the thoracic and abdomen regions using a training dataset of 50 patients. The models were then tested on an independent dataset of 15 patients using image similarity analysis assessing mean absolute error (MAE) and structural similarity index measure (SSIM) as metrics. VMAT‐based LRT plans were generated based on sCT and recalculated on the planning CT (pCT) for dosimetric accuracy comparison. Differences in dose volume histogram (DVH) metrics between pCT and sCT plans were assessed using the Wilcoxon signed‐rank test. Results The final sCT prediction model demonstrated high image similarity to pCT, with a MAE and SSIM of 38.93 ± 14.79 Hounsfield Units (HU) and 0.92 ± 0.05 for the thoracic region, and 73.60 ± 22.90 HU and 0.90 ± 0.03 for the abdominal region, respectively. There were no statistically significant differences between sCT and pCT plans in terms of organ‐at‐risk and target volume DVH parameters, including maximum dose (Dmax), mean dose (Dmean), dose delivered to 90% (D90%) and 50% (D50%) of target volume, except for minimum dose (Dmin) and (D10%). Conclusion With demonstrated high image similarity and adequate dose agreement between sCT and pCT, our study is a proof‐of‐concept for using deep learning predicted sCT for a simulation‐free treatment planning workflow for VMAT‐based LRT.
NCCN Guidelines® Insights: Survivorship, Version 2.2025
Sanft, Tara , Ansbaugh, Shannon M., Ariza‐Heredia, Ella , Ballinger, Tarah J. , Cohen, Stuart H. , Fairman, Nathan, Feliciano, Josephine , Flores, Tessa , Gabel, Nicolette , Goldman, Mindy, Hill‐Kayser, Christine E. , Hock, Karen , Kline‐Quiroz, Cristina , Koura, Divya, McDonough, Allison L. , Mooney, Kathi , Moryl, Natalie , Neuman, Heather B. , Patel, Chirayu G. , Peterson, Lindsay L. , Porpiglia, Andrea S., Saidain, Ava, Schapira, Lidia , Tenne, Laura, Ah, Diane Von , Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Tevaarwerk, Amyé , Ballinger, Tarah Jean , Day, Andrew T. , Armenian, Saro H. , Baker, Kevin Scott , Cathcart-Rake, Elizabeth , Evgeniou, Evgenios , Friedman, Debra L. , Lee, Nita Karnik , Moore, Halle C. F. , Overholser, Linda , Pirl, William F. , Rogers, Laura Q. , Smith, Sophia K. , Yang, Eric H. , Ah, Diane Von

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 11, 2025 | Volume: 23 | Issue: 6 | Pages: 208-217

10.6004/jnccn.2025.0028 | PMID 40499584 Get It

The NCCN Guidelines for Survivorship include screening, evaluation, and treatment recommendations for common physical and psychosocial problems resulting from adult-onset cancer and its treatment and provide a framework for coordination of survivorship care. They also include recommendations to help cancer survivors enhance their wellness and maintain a healthy lifestyle. These NCCN Guidelines Insights summarize the panel’s current recommendations and recent updates regarding physical activity, nutrition, and weight management for cancer survivors.
Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients
Tefferi, Ayalew , Alsugair, Ali, Gauto‐Mariotti, Estefania , Alhousani, Mohammad , Fathima, Saubia , Yousuf, Muhammad , Bolarinwa, Abiola , Foran, James M. , Mangaonkar, Abhishek A. , Litzow, Mark R. , Sproat, Lisa , Palmer, Jeanne , Matin, Aasiya , Ayala, Ernesto , Slack, James L., Porrata, Luis F. , Khera, Nandita , Punwani, Nathan , Gangat, Naseema , Patnaik, Mrinal M. , Fathima, Saubia , Bolarinwa, Abiola B , Mariotti, Estefania Gauto , Murthy, Hemant S. , Sproat, Lisa, Iqbal, Madiha , Kenderian, Saad S. , Chhabra, Saurabh , Hogan, William J. , Shah, Meera , Alkhateeb, Hassan B.

Mayo Clinic

No container title available | June 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6753879/v1 Get It

Abstract Allogeneic stem cell transplant (ASCT) remains the only curative option in chronic myelomonocytic leukemia (CMML). We retrospectively analyzed 138 CMML patients who underwent ASCT at the Mayo Clinic. Patients who transitioned to ASCT while in chronic phase (Group A) displayed superior post-transplant survival (PTS), compared to those in whom ASCT was performed after blast transformation (BT; Group B) (median 95 vs. 16 months; p=0.01). In Group A, PTS was superior in patients with <5% bone marrow (BM) blasts at time of ASCT (median 164 vs. 13.5 months; p=0.01). Other predictors of superior PTS included day-100 BM blast <5% or normal cytogenetics (median 164 vs 18 months; p=0.01) or presence of chronic graft-versus-host-disease (GVHD; median 164 vs. 26 months; p=0.01). Pre-ASCT hypomethylating agent exposure (HR=2.03; p=0.03), and receiving more than one line of pre-ASCT chemotherapy (p=0.01) predicted inferior PTS. In multivariable analysis, predictors of superior GVHD-free and relapse-free survival (GRFS) included the use myeloablative conditioning and the absence of morphologically or cytogenetically apparent disease at day-100. The use of post-transplant cyclophosphamide (PTCy) was associated with higher cumulative incidence of relapse (p=0.02) and numerically inferior PTS (p=0.1). Group B patients also appeared to benefit from achieving BM blast <5% at time of ASCT (p=0.4) as well as at day-100 (p=0.01), in terms of PTS, while full chimerism and normal cytogenetics at day-100 were associated with superior GRFS. These observations support the value of ASCT in CMML, especially if performed prior to BT and in the presence of <5% BM blasts at time of ASCT. Additionally, the observed detrimental impact of PTCy requires additional studies to confirm and investigate the underlying mechanisms.
Surgeon-Driven Variation in the Cost of Hip Arthroscopic Surgery for Labral Tears: A Time-Driven Activity-Based Costing Analysis
Dean, Michael C. , Cherian, Nathan J. , Dowley, Kieran , Torabian, Kaveh A. , LaPorte, Zachary L. , Dowley, Kieran S , Torabian, Kaveh A , Dean, M. Wingerchuk , Etges, Ana Paula Beck da Silva , Martin, Scott D.

Mayo Clinic

The American Journal of Sports Medicine | June 6, 2025 | Volume: 53 | Issue: 8 | Pages: 1869-1877

10.1177/03635465251341463 | PMID 40474356 Get It

Background: Amid mounting pressure to reduce health care spending, strategies for identifying and eliminating unwarranted variation in costs have garnered significant attention. Previous studies have characterized intersurgeon variation in costs for common orthopaedic procedures, but such variation remains unexplored in the context of hip arthroscopic surgery. Purpose: To (1) characterize variation in the cost of hip arthroscopic surgery between surgeons using time-driven activity-based costing (TDABC) and (2) identify patient characteristics, intraoperative findings, and operative procedures underlying such intersurgeon variation in costs. Study Design: Cohort study; Level of evidence, 3. Methods: Employing TDABC, the authors determined the intraoperative cost of 890 outpatient hip arthroscopic surgery cases performed by 5 surgeons at 4 surgery centers from 2015 to 2022. All costs were calculated in United States dollars. Costs were normalized to protect the confidentiality of internal hospital cost data. Surgeon-specific mean costs were calculated with and without adjustment for patient characteristics, surgical personnel, operative factors, and surgery center. Finally, to elucidate the sources of surgeon-driven cost variation, the authors estimated the proportion of variation attributable to different cost subcategories, including labor, implant/allograft, and other supply costs. Results: The intraoperative cost per patient ranged from 38.2 to 212.8 normalized cost units (mean, 100.0 ± 26.5), with a 1.6-fold variation in the mean cost between the highest and lowest cost surgeons. Operating surgeon alone explained 53.4% of the observed variation in costs. Controlling for case-specific features significantly improved the explanatory power to 91.8% ( P < .001), but the adjusted variation in costs between surgeons remained essentially unchanged (decreased by <3%). Each of the 5 surgeons generated costs that deviated significantly from those predicted based on case-specific factors, with mean surgeon deviations ranging from −5.0% to 21.8% ( P < .001 for all). Drivers of cost variation differed substantially between surgeons but generally stemmed from labor or other supply costs rather than implant/allograft costs. Conclusion: The cost of outpatient hip arthroscopic surgery varied widely between surgeons; the cause of this deviation was multifactorial and surgeon specific. While within-surgeon cost variation was effectively explained by patient and operative characteristics, most between-surgeon variability remained unexplained by observable factors. These insights may support individual surgeons in cost reduction efforts and, more importantly, may enable the alignment of reimbursement rates with costs.
How I Do It: Imaging Evaluation of Neonatal Bowel Obstructions
Hull, Nathan C. , Shabani, Abdusamea, Daltro, Pedro , Sodhi, Kushaljit Singh , Maxfield, Charles M. , Lee, Edward Y. , Maxfield, Charles

Mayo Clinic

Radiology | June 3, 2025 | Volume: 315 | Issue: 3 | Pages: No page available

10.1148/radiol.241778 | PMID 40459415 Get It

A practical patterned approach to neonatal bowel obstructions helps radiologists localize the obstruction and perform the appropriate imaging examination to accurately make the diagnosis and help guide proper management.
Association of Platelet Trajectory Patterns with In-Hospital Mortality in Critically Ill Adults with Acute Kidney Injury Receiving Continuous Renal Replacement Therapy
Clay, NR, Hernández, Diego Sánchez, Bui, Lan N. , Braun, Chloe G. , Renzi, Stefania, Tolwani, Ashita , Neyra, Javier A. , Takeuchi, Tomonori , Ekrikpo, Udeme E. , Lambert, Joshua , Clay, Nathan J., Kashani, Kianoush

Mayo Clinic

No container title available | June 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6502534/v1 | PMID 40502749 Get It

Abstract Background: Thrombocytopenia commonly occurs in critically ill patients with acute kidney injury (AKI) receiving continuous renal replacement therapy (CRRT) and is associated with poor outcomes. While previous studies have examined static platelet counts and relative declines, the prognostic significance of platelet trajectory patterns before and after CRRT initiation remains unclear. This study investigates the association between platelet count trajectories and in-hospital mortality in critically ill adult patients with AKI receiving CRRT. Methods: This study is a single-center retrospective cohort study utilizing electronic health record (EHR) data from critically ill adults (≥18 years) with AKI who received CRRT at the University of Alabama at Birmingham between January 2012 and December 2023. Platelet trajectories were assessed using mixed-effects models incorporating all platelet measurements within seven days before and after CRRT initiation. The slopes of platelet count change were categorized as descending (≤ -10 × 10³/μL/day), stable (-10 to 10), or ascending (≥ 10), creating a total of nine trajectory patterns by combining the three pre-CRRT and three during-CRRT categories. The primary outcome was in-hospital mortality, which was analyzed in relation to these trajectory patterns using logistic regression models adjusted for demographics, comorbidities, Sequential Organ Failure Assessment (SOFA) score, medications, and use of other organ support devices as covariates. Results: The study included 2,226 critically ill adults with AKI on CRRT, encompassing 8,569 patient-days before and 11,699 patient-days after CRRT initiation for platelet slope calculation. The median age was 59 years (IQR 48–69) and the median SOFA score at CRRT initiation was 12 (9–14). The in-hospital mortality rate was 57.8%. Before CRRT initiation, the most common trajectory was descending (46.2%), while after CRRT initiation, the stable pattern was most prevalent (58.3%). All patterns with a descending platelet trajectory during-CRRT were significantly associated with higher in-hospital mortality (aOR 1.92 [95% CI: 1.16–3.21] for ascending-descending; 1.49 [1.07–2.08] for stable-descending; 1.52 [1.04–2.23] for descending-descending). In contrast, all patterns with stable or increasing platelet counts during-CRRT tended to have lower mortality. Conclusions: A descending platelet trajectory after CRRT initiation was independently associated with increased in-hospital mortality.
Efficient Generation of Induced Pluripotent Stem Cell-Derived Definitive Endoderm Cells with Growth Factors and Small Molecules
Asumda, Faizal Z., Alzoubi, Shadia, Padarath, Kiyasha , John, Nina, Jones, Kimya , Kolhe, Ravindra , Mondal, Ashis K. , Lee, Tae Jin , Zhi, Wenbo , Huebert, Robert C. , Staff, Nathan P. , Kirkeby, Lindsey A., Mondal, Ashis Kumar , Huebert, Robert , Staff, Nathan P , Kolhe, Ravindra , John, Nina

Mayo Clinic

Cells | June 2, 2025 | Volume: 14 | Issue: 11 | Pages: 815

10.3390/cells14110815 | PMID 40497991 Get It

Definitive endoderm (DE) differentiation leads to the development of the major internal organs including the liver, intestines, pancreas, gall bladder, prostate, bladder, thyroid, and lungs. The two primary methods utilized for in vitro differentiation of induced pluripotent stem cells (iPSCs) into DE cells are the growth factor (GF) and the small molecule (SM) approaches. The GSK-3 inhibitor (CHIR99021) is a key factor for the SM approach. Activin A and Wnt3a are utilized in the GF approach. In this study, both the GF and SM protocols were compared to each other. The results show that both the GF and SM protocol produce DE with a similar morphological phenotype, gene and protein expression, and a similar level of homogeneity and functionality. However, on both the gene expression and proteomic level, there is a divergence between the two protocols during hepatic specification. Proteomic analysis shows that hepatoblasts from the GF protocol have significantly differentially expressed proteins (DEPs) involved in liver metabolic pathways compared to the SM protocol. Well-validated DE differentiation protocols are needed to fully unlock the clinical potential of iPSCs. In the first step of generating DE-derived tissue, either protocol can be utilized. However, for hepatic specification, the GF protocol is more effective.
Biomarkers of Cellular Senescence in Type 2 Diabetes Mellitus
Hoong, Caroline Wei Shan , White, Thomas A. , Atkinson, Elizabeth J. , Tweed, Amanda, Sfeir, Jad , Khosla, Sundeep , Hoong, Caroline, Sfeir, Jad G , Khosla, Sundeep , Hoong, Caroline W S , Farr, Joshua N. , Monroe, David G. , White, Thomas A., Palmer, Allyson K. , LeBrasseur, Nathan K.

Mayo Clinic

Aging Cell | May 31, 2025 | Volume: 24 | Issue: 8 | Pages: No page available

10.1111/acel.70120 | PMID 40448295 Get It

ABSTRACT Although animal studies have linked cellular senescence to the pathogenesis and complications of type 2 diabetes mellitus (T2DM), there is a paucity of corroborating data in humans. Thus, we measured a previously validated marker for senescent cell burden in humans, T‐cell expression of p16 mRNA, along with additional biomarkers, to compare the senescence phenotypes of postmenopausal control (lean, N = 37) and T2DM ( N = 27) participants. To control for effects of obesity alone, we included a third group of obese but non‐diabetic women ( N = 29) who were matched for body mass index to the T2DM participants. In addition, given the increase in fracture risk in T2DM despite preserved or even increased bone mineral density, we related these senescence biomarkers in the T2DM participants to skeletal microarchitectural parameters. Relative to the lean participants, T‐cell p16 and p21 Cip1 expression was increased in the T2DM, but not the obese, non‐diabetic participants. Expression of p16 and p21 Cip1 was positively associated with HbA1c and an index of skin advanced glycation end‐products. T2DM was also associated with an increase in a number of SASP factors. Among participants with T2DM, women in the highest tertile for T‐cell expression of p16 had significantly reduced tibial cortical area and thickness as compared to those in the lower two tertiles. Overall, our studies link cellular senescence to metabolic and skeletal alterations in T2DM and point to the need for further studies evaluating the role of cellular senescence in mediating skeletal fragility, as well as potentially other complications in T2DM.
A phase II study of pemetrexed and pembrolizumab in patients (pts) with recurrent and/or metastatic (R/M) salivary gland cancer (SGC): Results from non-adenoid cystic cohort.
Price, Katharine A. , Foster, Nathan R. , Asmus, Erik, Fazer-Posorske, Casey , Meyers, Jordan E., Oltmans, Alaina D., Savvides, Panos, Zhao, Yujie , Cooper, Anna C., Baral, Binav, Fuentes, Harry E , Savvides, Panos, McGarrah, Patrick W. , Chintakuntlawar, Ashish V.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 6106-6106

10.1200/jco.2025.43.16_suppl.6106 Get It

6106 Background: Treatment options for pts with R/M SGC are limited. Responses to chemotherapy (CT) are low with high toxicity and responses to immune checkpoint inhibition (ICI) are <10%. Pemetrexed (PTX) is safe and tolerable with responses reported in pts with R/M SGC. 1 Given enhanced responses with PTX and pembrolizumab (PMB) for lung cancer, we hypothesized that PTX and PMB will have activity for SGC. Herein we present the efficacy results in pts with non-adenoid cystic carcinoma (ACC). Methods: MC200708 is a single arm phase II study of PTX and PMB in pts with R/M SGC (NCT04895735). Pts were treated in 2 cohorts: ACC (cohort A) and non-ACC (cohort B). Key eligibility criteria: ≥18 years, ECOG 0-1, measurable disease. Prior ICI and/or PTX was allowed. Key exclusion criteria: serious comorbidities, autoimmune disease, and brain metastases. Simon’s 2-stage design was used for each cohort. Primary endpoint was overall response rate (ORR). Secondary endpoints: progression free survival (PFS), overall survival (OS), and toxicity. All pts received PTX 500 mg/m2 IV + PMB 200 mg IV q3 weeks until progression or treatment intolerance. Imaging was q3 cycles. Results: 25 pts were enrolled Aug 2021-Feb 2024; 1 cancelled prior to treatment. Of 24 eligible and treated pts, median age was 59.5 years (46-77), 66.7% male, performance status 0 (62.5%) or 1 (37.5%). Histologies were salivary duct carcinoma (SDC, 11), acinic cell carcinoma (8), mucoepidermoid carcinoma (MEC, 3), myoepithelial carcinoma (1), and carcinoma NOS (1). 7 pts had no prior therapies (29.2%). The remaining pts had 1 (33.3%), 2 (29.2%), or ≥ 3 lines of therapy (8.3%). 83.3% of pts had no prior ICI. Median cycles of treatment was 8 (2-34), and duration of response was 12.5 months (4.1-20.6). 9 of 24 pts had a confirmed partial response (PR) for ORR of 37.5% (CI: 18.8-59.4). PRs were seen in 7 pts with SDC (7 of 11, 63.6% PR), 1 with MEC, and 1 with acinic cell. Stable disease (SD) was seen in 5 (20.8%), progressive disease in 8 (33.3%), and 2 didn’t have post-baseline imaging, but were considered non-responders per protocol. Clinical benefit rate was 58.3% (CI: 36.6-77.9). With median follow-up of 12.0 months (2-34.7), median OS is 20.7 months (CI: 17.3-not reached) and median PFS is 6.2 months (CI: 2.1-17.3). 1-year OS and PFS rate is 76.3% (95% CI: 59.9-97.2) and 36.1% (CI: 21.01-62.2), respectively. Common toxicities were grade 1 fatigue and nausea. 6 pts (25.0%) had ≥1 grade 3-4 toxicity possibly related to treatment, mostly hematologic. The 4 pts with grade 3-4 non-heme toxicity had grade 3 fatigue, rash, and heart failure, and 1 grade 4 hypokalemia. Correlative studies investigating biomarkers of response are underway. Conclusions: PTX and PMB has activity in pts with R/M SGC, with promising responses in pts with SDC and median response duration of 1 year. 1 Viscuse et al. Head Neck 2019;41(6):E99-103. Clinical trial information: NCT04895735 .